Coherus BioSciences (CHRS) to Release Earnings on Wednesday

Coherus BioSciences (NASDAQ:CHRSGet Free Report) will be posting its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Coherus BioSciences to post earnings of ($0.10) per share for the quarter.

Coherus BioSciences (NASDAQ:CHRSGet Free Report) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.10. The company had revenue of $64.98 million during the quarter, compared to analyst estimates of $57.08 million. On average, analysts expect Coherus BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coherus BioSciences Trading Down 1.9 %

Shares of NASDAQ CHRS opened at $0.74 on Thursday. Coherus BioSciences has a twelve month low of $0.71 and a twelve month high of $3.73. The company has a market capitalization of $84.43 million, a price-to-earnings ratio of -0.96 and a beta of 0.65. The firm has a 50-day moving average of $1.10 and a two-hundred day moving average of $1.52.

Wall Street Analysts Forecast Growth

CHRS has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Coherus BioSciences in a report on Monday, September 16th. StockNews.com downgraded shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a report on Saturday, October 19th. Finally, UBS Group downgraded shares of Coherus BioSciences from a “buy” rating to a “neutral” rating and cut their price target for the company from $4.00 to $1.50 in a report on Friday, August 16th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $7.13.

Read Our Latest Report on Coherus BioSciences

Coherus BioSciences Company Profile

(Get Free Report)

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.

Further Reading

Earnings History for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.